Estimation and external validation of a new prognostic model for predicting recurrence-free survival for early breast cancer patients in the UK

British Journal of Cancer

Volumn 103, Issue 6, 2010, Pages 776-786

  Campbell, H E ^a   Gray, A M ^a   Harris, A L ^b   Briggs, A H ^c   Taylor, M A ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

early breast cancer; prognostic model; recurrence; survival analysis

Indexed keywords

ADULT; AGED; ALGORITHM; BREAST TUMOR; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RECURRENT DISEASE; RISK; THEORETICAL MODEL; UNITED KINGDOM; VALIDATION STUDY;

ADULT; AGED; ALGORITHMS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GREAT BRITAIN; HUMANS; MIDDLE AGED; MODELS, THEORETICAL; PROGNOSIS; RECURRENCE; RISK;

EID: 77956432342     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605863     Document Type: Article

References (50)

1. Adjuvant! Online (2005) Adjuvant! Breast Cancer Help Files. https://www.adjuvantonline.com/breasthelp0306/breastindex.html. Accessed 11 April 2007
2. Akaike H (1974) A new look at the statistical model identification. Transact Autom Control 19: 716-723
3. Albain KS, Allred DC, Clark GM (1994) Breast cancer outcome and predictors of outcome: are there age differentials? J Natl Cancer Inst Monogr 16: 35-42
4. Altman DG, Lyman GH (1998) Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res Treat 52: 289-303
5. Altman DG, Royston P (2000) What do we mean by validating a prognostic model? Stat Med 19: 453-473
6. Blamey RW (1996) 4. The design and clinical use of the Nottingham Prognostic Index in breast cancer. Breast 5: 156-157
7. Blamey RW, Davies CJ, Elston CW, Johnson J, Haybittle JL, Maynard PV (1979) Prognostic factors in breast cancer-the formation of a prognostic index. Clin Oncol 5: 227-236
8. Blamey RW, Pinder SE, Ball GR, Ellis IO, Elston CW, Mitchell MJ, Haybittle JL (2007) Reading the prognosis of the individual with breast cancer. Eur J Cancer 43: 1545-1547
9. Bradburn MJ, Clark TG, Love SB, Altman DG (2003) Survival analysis Part III: multivariate data analysis-choosing a model and assessing its adequacy and fit. Br J Cancer 89: 605-611
10. Brier GW (1950) Verification of forecasts expressed in terms of probability. Mon Wea Rev 78: 1-3
11. Campbell HE, Taylor MA, Harris AL, Gray AM (2009) An investigation into the performance of the ADJUVANT! Online prognostic programme in early breast cancer for a cohort of patients in the UK. Br J Cancer 101: 1074-1084
12. Cancer Information Section-International Agency for Research on Cancer (2008) World Health Organisation (WHO) Mortality Database. http://www-dep.iarc. fr/. Accessed 1 May 2009
13. Cancer Research UK (2009) Breast screening in the UK-a brief history. http://info.cancerresearchuk.org/cancerstats/types/breast/screening/history/. Accessed 8 April 2009
14. Chang JC, Hilsenbeck SG (2004) Prognostic, predictive markers. In Diseases of the Breast, Harris JR, Lippman ME, Morrow M, Osborne CK (eds) 3rd edn, pp 675-696. Lippincott, Williams and Wilkins: Philadelphia
15. Chie WC, Huang CS, Chen JH, Chang KJ (2000) Utility assessment for different clinical phases of breast cancer in Taiwan. J Formo Med Assoc 99: 677-683
16. Clark TG, Altman DG (2003) Developing a prognostic model in the presence of missing data: an ovarian cancer case study. J Clin Epidemiol 56: 28-37
17. Clark TG, Altman DG, De Stavola BL (2002) Quantification of the completeness of follow-up. Lancet 359: 1309-1310
18. Conner-Spady B, Cumming C, Nabholtz JM, Jacobs P, Stewart D (2001) Responsiveness of the EuroQol in breast cancer patients undergoing high dose chemotherapy. Qual Life Res 10: 479-486
19. Cox DR (1957) Note on Grouping. J Am Stat Soc 52: 543-547
20. De La Rochefordiere A, Asselain B, Campana F, Scholl SM, Fenton J, Vilcoq JR, Durand JC, Pouillart P, Magdelenat H, Fourquet A (1993) Age as prognostic factor in premenopausal breast carcinoma. Lancet 341: 1039-1043
21. Early Breast Cancer Trialists' Collaborative Group (2005a) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717
22. Early Breast Cancer Trialists' Collaborative Group (2005b) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366: 2087-2106
23. Galea M, Blamey R, Elston C, Ellis I (1992) The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22: 207-219
24. Harrell Jr FE, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15: 361-387
25. Haybittle JL, Blamey RW, Elston CW, Johnson J, Doyle PJ, Campbell FC, Nicholson RI, Griffiths K (1982) A prognostic index in primary breast cancer. Br J Cancer 45: 361-366
26. Hosmer D, Lemeshow S (1999) Applied Survival Analysis: Regression Modelling of Time to Event Data. Wiley: New York
27. Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, de Matteis A, Stewart A, Eiermann W, Szakolczai I, Palmer M, Schumacher M, Geberth M, Lisboa B (2002) Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the zoladex early breast cancer research association study. J Clin Oncol 20: 4628-4635
28. Mackillop WJ, Quirt CF (1997) Measuring the accuracy of prognostic judgments in oncology. J Clin Epidemiol 50: 21-29
29. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93: 387-391 (Pubitemid 43080010)
30. Nixon AJ, Neuberg D, Hayes DF, Gelman R, Connolly JL, Schnitt S, Abner A, Recht A, Vicini F, Harris JR (1994) Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol 12: 888-894 (Pubitemid 24145313)
31. Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, Davis GJ, Chia SK, Gelmon KA (2005) Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23: 2716-2725
32. Peduzzi P, Concato J, Feinstein AR, Holford TR (1995) Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 48: 1503-1510 (Pubitemid 26035533)
33. Ravdin P, Siminoff L, Davis G, Mercer M, Hewlett J, Gerson N, Parker H (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19: 980-991
34. Royston P (2004) Multiple imputation of missing values. Stata J 4: 227-241
35. Royston P, Altman D (1994) Regression using fractional polynomials of continuous covariates: parsimonious parametric modelling. Appl Stat 43: 429-467
36. Sainsbury R, Johnston C, Haward B (1999) Effect on survival of delays in referral of patients with breast-cancer symptoms: a retrospective analysis. Lancet 353: 1132-1135
37. Sauerbrei W, Royston P (1999) Building multivariable prognostic and diagnostic models: transformation of the predictors by using fractional polynomials. J R Stat Soc Ser A (Stat Soc) 162: 71-94
38. Sauerbrei W, Royston P, Bojar H, Schmoor C, Schumacher M (1999) Modelling the effects of standard prognostic factors in node-positive breast cancer. German Breast Cancer Study Group (GBSG). Br J Cancer 79: 1752-1760
39. Sauerbrei W, Schumacher M, Cuzick J, Jonat W, Kaufmann M (2003) Prognostic factors determine groups with different prognoses in pre-and perimenopausal women with estrogen receptorpositive, node-positive breast cancer treated with goserelin (Zoladexs) or CMF-results from the ZEBRA study. Breast Cancer Res Treat 82: S121
40. Shafer J, Olsen M (1998) Multiple imputation for multivariate missing-data problems: a data analyst's perspective. Multivariate Behav Res 33: 545-571
41. Siminoff LA, Gordon NH, Silverman P, Budd T, Ravdin PM (2006) A decision aid to assist in adjuvant therapy choices for breast cancer. Psychooncology 15: 1001-1013
42. Sorensen S, Brown R, Benedict A, Flood E, Revicki D (2004) Patient-Rated Utilities in Postmenopausal Early Breast Cancer: A Cross Country Comparison. ISPOR Seventh Annual European Congress: Hamburg
43. The Adjuvant Breast Cancer Trials Collaborative Group (2007a) Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial. J Natl Cancer Inst 99: 516-525
44. The Adjuvant Breast Cancer Trials Collaborative Group (2007b) Poly-chemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial. J Natl Cancer Inst 99: 506-515
45. Todd J, Dowle C, Williams M, Elston C, Ellis I, Hinton C, Blamey R, Haybittle J (1987) Confirmation of a prognostic index in primary breast cancer. Br J Cancer 56: 489-492 (Pubitemid 17146357)
46. van Buuren S, Boshuizen HC, Knook DL (1999) Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 18: 681-694
47. Verschraegen CM, Vinh-Hung VM, Cserni GM, Gordon RP, Royce MEM, Vlastos GM, Tai PM, Storme GM (2005) Modeling the effect of tumor size in early breast cancer. Ann Surg 241: 309-318
48. Walker R (2003) Prognostic and Predictive Factors in Breast Cancer, 1st edn Martin Dunitz: London
49. Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, Glanville J, Gray A, Harris A, Johnston K, Lodge M (2006) Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. Health Technol Assess 10(34): 1-222
50. Wishart G, Azzato E, Greenberg D, Rashbass J, Kearins O, Lawrence G, Caldas C, Pharoah P (2010) PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res 12(1): R1